Furihata, Hirotake

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide

Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 89

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 73

Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders

Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 47

Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding

Yamada, K., Shioya, R., Nishino, K., Furihata, H., Hijikata, A., Kaneko, M. K., Kato, Y., Shirai, T., Kosako, H., & Sawasaki, T. (2023) · Nature Communications

Biotin and Related StudiesHER2/EGFR in Cancer Research

Cited by 18